Catalent introduces Peel-ID safe storage label to improve storage and retrieval of patient kits
Peel-ID greatly reduces the risk of human error resulting from the incorrect kit being pulled from inventory due to illegible handwriting or incorrectly transposed numbers.
Catalent Pharma Solutions has introduced its Peel-ID label, a new standard for clinical supply labeling that helps to reduce the risk of patients receiving the incorrect medication at clinical sites.
The patent-ending clinical label comprises a permanent portion, and a peel-off label containing the patient kit identifier, which can be removed by site personnel and affixed elsewhere on the patient kit to better facilitate storage, inventory management and quick retrieval. Peel-ID labels are designed and printed in-house by Catalent and are available in a variety of standard sizes and designs to fit most patient kits.
The Peel-ID label was developed in response to some sites manually writing kit identification numbers on an unlabeled side of a package, because the label is obscured due to the way the kits are stored. With a Peel-ID label, the risk of human error resulting from the incorrect kit being pulled from inventory due to illegible handwriting or incorrectly transposed numbers is greatly reduced.
“Our clinical site liaisons recognized the potential for harm from this practice and engaged our employees to develop an innovative and practical solution,” said Esther Sadler-Williams, Global Director Strategic Development and Innovation at Catalent. “Peel-ID will now be our standard recommendation to customers for all patient kits packaged by Catalent, reducing risks to patient safety.”
”The innovative Peel-ID label gives clinical sites increased flexibility in their storage options whilst being confident that an integral, approved label can be used on any surface of the kit,” added Dr. Samantha Carmichael, Lead Pharmacist Clinical Trials, Clinical Research & Development, NHS Greater Glasgow & Clyde. “This could streamline the dispensing process for patients at sites that hold a lot of stock, and those that undertake a manual transcription process can be confident in a reduced risk of errors.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance